Haemonetics Corp

Organisation

125 Summer Street, Boston, MA, United States, 02110

Headquarters

3023

Employees

Health Technology

Industry

Christopher Simon

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Price

Target

Haemonetics Corp (HAE) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Haemonetics Corp (HAE) share price will touch around $87.5 in next 12-months.

Currently 11 wall-street analysts regularly analyze the financials of Haemonetics Corp on a frequent basis to provide recommendations along with target share price. 11 analysts offering 12-month price forecasts for Haemonetics Corp (HAE) have a share price target of $87.5. This median of share price forecast represents a 46.98% upside from the latest price of $59.53 as on 19.03.26.

Haemonetics Corp (HAE) Share Price Forecast

Home

US Stocks

Haemonetics Corp (HAE)

Haemonetics Corp Stock Forecast

Haemonetics Corp Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Haemonetics Corp (HAE): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Haemonetics Corp's share price and its median forecast price. As on 19.03.26, the difference is -10.24%

Haemonetics Corp Forecast and Target Price

Haemonetics Corp (HAE) Share Price Forecast

Haemonetics Corp (HAE) Price vs Consensus Price Target

Haemonetics Corp (HAE) Share Price Forecast v/s Share Price Today

Haemonetics Corp (HAE): Difference between Current Price & Median Forecasted Price

Haemonetics Corp (HAE) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price